Ignace Vergote

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Physiology

Postmenopause

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Cadron Isabelle; Van Gorp Toon; Timmerman Dirk; Amant Frederic; Waelkens Etienne; Vergote Ignace
Application of proteomics in ovarian cancer: which sample should be used?
Dieudonné A S; Lambrechts D; Claes B; Vandorpe T; Wildiers H; Timmerman D; Billen J; Leunen K; Amant F; Berteloot P; Smeets A; Paridaens R; Weltens C; Van Limbergen E; Van den Bogaert W; Vergote I; Van Huffel S; Christiaens M R; Neven P
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Vergote Ignace; Amant Frederic; Neven Patrick
Is it safe to treat endometrial carcinoma endoscopically?

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Ignace Vergote (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Cadron Isabelle; Van Gorp Toon; Timmerman Dirk; Amant Frederic; Waelkens Etienne; Vergote Ignace
Application of proteomics in ovarian cancer: which sample should be used?
Gynecologic oncology 2009;115(3):497-503.
2009: Dieudonné A S; Lambrechts D; Claes B; Vandorpe T; Wildiers H; Timmerman D; Billen J; Leunen K; Amant F; Berteloot P; Smeets A; Paridaens R; Weltens C; Van Limbergen E; Van den Bogaert W; Vergote I; Van Huffel S; Christiaens M R; Neven P
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Breast cancer research and treatment 2009;118(3):531-8.
2009: Vergote Ignace; Amant Frederic; Neven Patrick
Is it safe to treat endometrial carcinoma endoscopically?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5305-7.
2009: Vandenput Ingrid; Vergote Ignace; Leunen Karin; Berteloot Patrick; Neven Patrick; Amant Frédéric
Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(6):1147-51.
2009: Vandenput I; Van Calster B; Capoen A; Leunen K; Berteloot P; Neven P; Moerman Ph; Vergote I; Amant F
Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
British journal of cancer 2009;101(2):244-9.
2009: Amant Frédéric; Van Calsteren Kristel; Halaska Michael J; Beijnen Jos; Lagae Lieven; Hanssens Myriam; Heyns Liesbeth; Lannoo Lore; Ottevanger Nelleke P; Vanden Bogaert Walter; Ungar Laszlo; Vergote Ignace; du Bois Andreas
Gynecologic cancers in pregnancy: guidelines of an international consensus meeting.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19 Suppl 1():S1-12.
2009: Vergote Ignace; Calvert Hilary; Kania Marek; Kaiser Christopher; Zimmermann Annamaria Hayden; Sehouli Jalid
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
European journal of cancer (Oxford, England : 1990) 2009;45(8):1415-23.
2009: Brouckaert Olivier; Pintens Saskia; Van Belle Vanya; Van Huffel Sabine; Camerlynck Edward; Amant Frédéric; Leunen Karin; Smeets An; Berteloot Patrick; Van Limbergen Erik; Decock Julie; Hendrickx Wouter; Weltens Caroline; Van den Bogaert Walter; Vanden Bempt Isabelle; Drijkoningen Maria; Paridaens Robert; Wildiers Hans; Vergote Ignace; Christiaens Marie-Rose; Neven Patrick
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Breast cancer research and treatment 2009;115(2):349-58.
2009: Cadron Isabelle; Van Gorp Toon; Amant Frederic; Vergote Ignace; Moerman Philippe; Waelkens Etienne; Daemen Anneleen; Van De Plas Raf; De Moor Bart; Zeillinger Robert
The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.
Anticancer research 2009;29(4):1039-45.
2009: Vergote Ignace; Amant Frederic; Van Gorp Toon
Role of diaphragmatic surgery in 69 patients with ovarian carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(3):481.
2009: van Wijk F H; van der Burg M E L; Burger Curt W; Vergote Ignace; van Doorn H C
Management of surgical stage III and IV endometrioid endometrial carcinoma: an overview.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(3):431-46.
2009: van Wijk F H; van der Burg M E L; Burger Curt W; Vergote Ignace; van Doorn Helena C
Management of recurrent endometrioid endometrial carcinoma: an overview.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(3):314-20.
2009: Amant Frédéric; Neven Patrick; Vergote Ignace
Lymphadenectomy in endometrial cancer.
Lancet 2009;373(9670):1169-70; author reply 1170-1.
2009: Vergote Ignace; Amant Frédéric; Ameye Lieveke; Timmerman Dirk
Screening for ovarian carcinoma: not quite there yet.
The lancet oncology 2009;10(4):308-9.
2009: Petru Edgar; Lück Hans-Joachim; Stuart Gavin; Gaffney David; Millan David; Vergote Ignace;
Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system.
European journal of obstetrics, gynecology, and reproductive biology 2009;143(2):69-74.
2009: Coosemans An; Moerman Philippe; Vergote Ignace; Koninckx Philippe R; Van Gool Stefaan W; Amant Frédéric
Wilms' tumor gene 1 (WT1) overexpression in neurons in deep endometriosis: a pilot study.
Fertility and sterility 2009;91(4 Suppl):1441-4.
2009: Van Calsteren Kristel; Devlieger Roland; De Catte Luc; D'Hooghe Thomas; Chai Daniel C; Mwenda Jason M; Vergote Ignace; Amant Frédéric
Feasibility of ultrasound-guided percutaneous samplings in the pregnant baboon: a model for studies on transplacental transport.
Reproductive sciences (Thousand Oaks, Calif.) 2009;16(3):280-5.
2009: Amant Frédéric; Coosemans An; Renard Vincent; Everaert Els; Vergote Ignace
Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(2):245-8.
2009: Coosemans A; Van Hove Th; Verbist G; Moons L; Neven P; Moerman Ph; Vergote I; Van Gool S W; Amant F
Wilms' tumour gene 1 (WT1) positivity in endothelial cells surrounding epithelial uterine tumours.
Histopathology 2009;54(3):384-7.
2009: Timmers P J; Zwinderman A H; Teodorovic I; Vergote I; Trimbos J B
Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(1):88-93.
2009: Ameye L; Valentin L; Testa A C; Van Holsbeke C; Domali E; Van Huffel S; Vergote I; Bourne T; Timmerman D
A scoring system to differentiate malignant from benign masses in specific ultrasound-based subgroups of adnexal tumors.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2009;33(1):92-101.
2009: Vandenput I; Van Eygen K; Moerman Ph; Vergote I; Amant F
Ineffective attempt to preserve fertility with a levonorgestrel-releasing intrauterine device in a young woman with endometrioid endometrial carcinoma: a case report and review of the literature.
European journal of gynaecological oncology 2009;30(3):313-6.
2009: Daemen Anneleen; Gevaert Olivier; Leunen Karin; Legius Eric; Vergote Ignace; De Moor Bart
Supervised classification of array CGH data with HMM-based feature selection.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 2009;():468-79.
2009: Vandenput I; Vanden Bempt I; Leunen K; Neven P; Berteloot P; Moerman P; Vergote I; Amant F
Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports.
Gynecologic and obstetric investigation 2009;67(1):46-8.
2008: Vergote Ignace; Tsolakidis Dimitris; Mortier Dieter; Neven Patrick; Amant Frederic; Mottaghy Felix; Van Limbergen Erik
Value of positron emission tomography of the para-aortic lymph nodes in cervical carcinoma stage IB2-IIIB.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5654-5; author reply 5655-7.
2008: Coosemans An; Moerman Philippe; Verbist Godelieve; Maes Wim; Neven Patrick; Vergote Ignace; Van Gool Stefaan W; Amant Frédéric
Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
Gynecologic oncology 2008;111(3):502-8.
2008: Verguts Jasper; Vergote Ignace; Amant Frederic; Moerman Philippe; Koninckx Philippe
The addition of 4% oxygen to the CO(2) pneumoperitoneum does not decrease dramatically port site metastases.
Journal of minimally invasive gynecology 2008;15(6):700-3.
2008: Amant Frédéric; Van Calsteren Kristel; Vergote Ignace; Ottevanger Nelleke
Gynecologic oncology in pregnancy.
Critical reviews in oncology/hematology 2008;67(3):187-95.
2008: Morales Leilani; Pans Steven; Verschueren Kilian; Van Calster Ben; Paridaens Robert; Westhovens Rene; Timmerman Dirk; De Smet Luc; Vergote Ignace; Christiaens Marie-Rose; Neven Patrick
Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(19):3147-52.
2008: Mortier D G; Stroobants S; Amant F; Neven P; VAN Limbergen E; Vergote I
Laparoscopic para-aortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2-IIIB.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(4):723-9.
2008: Neven P; Van Calster B; Van den Bempt I; Van Huffel S; Van Belle V; Hendrickx W; Decock J; Wildiers H; Paridaens R; Amant F; Leunen K; Berteloot P; Timmerman D; Van Limbergen E; Weltens C; Van den Bogaert W; Smeets A; Vergote I; Christiaens M R; Drijkoningen M
Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
Breast cancer research and treatment 2008;110(1):153-9.
2008: Timmerman D; Testa A C; Bourne T; Ameye L; Jurkovic D; Van Holsbeke C; Paladini D; Van Calster B; Vergote I; Van Huffel S; Valentin L
Simple ultrasound-based rules for the diagnosis of ovarian cancer.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2008;31(6):681-90.
2008: Neven Patrick; Paridaens Robert; Pelgrims Gino; Martens Marc; Bols Alain; Goeminne Jean Charles; Vindevoghel Anita; Demol Jan; Stragier Barbara; De Greve Jacques; Fontaine Christel; Van Den Weyngaert Danielle; Becquart Dominique; Borms Marleen; Cocquyt Veronique; Van Den Broecke Rudy; Selleslags Jean; Awada Ahmad; Dirix Luc; Van Dam Peter; Azerad Marie Agnes; Vandenhoven Guy; Christiaens Marie Rose; Vergote Ignace
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
Breast cancer research and treatment 2008;109(1):59-65.
2008: Neven Patrick; Brouckaert Olivier; Van Belle Vanya; Vanden Bempt Isabelle; Hendrickx Wouter; Cho Hyonil; Deraedt Karen; Van Calster Ben; Van Huffel Sabine; Moerman Philippe; Amant Frederic; Leunen Karin; Smeets Ann; Wildiers Hans; Paridaens Robert; Vergote Ignace; Christiaens Marie-Rose
In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1768-9; author reply 1769-71.
2008: Vergote Ignace; Amant Frederic; Leunen Karin; Cadron Isabelle; Van Gorp Toon; Neven Patrick; Berteloot Patrick
Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.
The oncologist 2008;13(4):410-4.
2008: Vergote I; van Gorp T; Amant F; Leunen K; Neven P; Berteloot P
Timing of debulking surgery in advanced ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18 Suppl 1():11-9.
2008: Devolder K; Amant F; Neven P; van Gorp T; Leunen K; Vergote I
Role of diaphragmatic surgery in 69 patients with ovarian carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(2):363-8.
2008: Van der Zee Ate G J; Oonk Maaike H; De Hullu Joanne A; Ansink Anca C; Vergote Ignace; Verheijen René H; Maggioni Angelo; Gaarenstroom Katja N; Baldwin Peter J; Van Dorst Eleonore B; Van der Velden Jacobus; Hermans Ralph H; van der Putten Hans; Drouin Pierre; Schneider Achim; Sluiter Wim J
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(6):884-9.
2008: De Maeyer Leen; Van Limbergen Erik; De Nys Katelijne; Moerman Philippe; Pochet Nathalie; Hendrickx Wouter; Wildiers Hans; Paridaens Robert; Smeets Ann; Christiaens Marie-Rose; Vergote Ignace; Leunen Karin; Amant Frederic; Neven Patrick
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):335-6; author reply 336-8.
2008: Leunen Karin; Drijkoningen Maria; Neven Patrick; Christiaens Maria-Rose; Van Ongeval Chantal; Legius Eric; Amant Frédéric; Berteloot Patrick; Vergote Ignace
Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?
Breast cancer research and treatment 2008;107(1):79-86.
2008: Vergote Ignace; Pouseele Bram; Van Gorp Toon; Vanacker Bernard; Leunen Karin; Cadron Isabelle; Neven Patrick; Amant Frederic
Robotic retroperitoneal lower para-aortic lymphadenectomy in cervical carcinoma: first report on the technique used in 5 patients.
Acta obstetricia et gynecologica Scandinavica 2008;87(7):783-7.
2008: Kalogiannidis I; Bobos M; Papanikolaou A; Makedos A; Amplianitis I; Vergote I; Nenopoulou E; Makedos G
Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes.
European journal of gynaecological oncology 2008;29(1):19-25.
2008: Van Calsteren Kristel; Hanssens Myriam; Moerman Philippe; Orye Guy; Bielen Didier; Vergote Ignace; Amant Frederic
Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy.
Acta obstetricia et gynecologica Scandinavica 2008;87(2):250-3.
2008: Gevaert Olivier; De Smet Frank; Van Gorp Toon; Pochet Nathalie; Engelen Kristof; Amant Frederic; De Moor Bart; Timmerman Dirk; Vergote Ignace
Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation.
BMC cancer 2008;8():18.
2007: Vergote Ignace; van der Zee Ate G J; Kesic Vesna; Sert Bilal; Robova Helena; Rob Lukas; Reed Nicholas; Luesley David M; Leblanc Eric; Hagen Bjorn; Gitsch Gerald; du Bois Andreas; di Vagno Giovanni; Colombo Nicoletta; Beller Uziel; Ayhan Ali; Jacobs Ian
ESGO statement on cervical cancer vaccination.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(6):1183-5.
2007: Amant F; De Knijf A; Van Calster B; Leunen K; Neven P; Berteloot P; Vergote I; Van Huffel S; Moerman P
Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma.
British journal of cancer 2007;97(9):1194-9.
2007: Van Mieghem T; Leunen K; Pochet N; De Moor B; De Smet F; Amant F; Berteloot P; Timmerman D; Vanden Bempt I; Drijkoningen R; Wildiers H; Paridaens R; Smeets A; Hendrickx W; Van Limbergen E; Christiaens M R; Vergote I; Neven P
Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age.
Breast cancer research and treatment 2007;106(1):127-33.
2007: Caluwaerts Silvia; Lambin Suzan; van Bree Rita; Peeters Herman; Vergote Ignace; Verhaeghe Johan
Diet-induced obesity in gravid rats engenders early hyperadiposity in the offspring.
Metabolism: clinical and experimental 2007;56(10):1431-8.
2007: Cadron Isabelle; Van Gorp Toon; Amant Frederic; Leunen Karin; Neven Patrick; Vergote Ignace
Chemotherapy for recurrent cervical cancer.
Gynecologic oncology 2007;107(1 Suppl 1):S113-8.
2007: Amant Frederic; Moerman Philippe; Neven Patrick; Timmerman Dirk; Van Limbergen Erik; Vergote Ignace
Treatment modalities in endometrial cancer.
Current opinion in oncology 2007;19(5):479-85.
2007: Timmerman Dirk; Van Calster Ben; Jurkovic Davor; Valentin Lil; Testa Antonia C; Bernard Jean-Pierre; Van Holsbeke Caroline; Van Huffel Sabine; Vergote Ignace; Bourne Tom
Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4194-200.
2007: Verguts J; Amant F; Moerman Ph; Vergote I
HPV induced ovarian squamous cell carcinoma: case report and review of the literature.
Archives of gynecology and obstetrics 2007;276(3):285-9.
2007: Van Holsbeke Caroline; Van Calster Ben; Valentin Lil; Testa Antonia C; Ferrazzi Enrico; Dimou Ioannis; Lu Chuan; Moerman Philippe; Van Huffel Sabine; Vergote Ignace; Timmerman Dirk;
External validation of mathematical models to distinguish between benign and malignant adnexal tumors: a multicenter study by the International Ovarian Tumor Analysis Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4440-7.
2007: Cadron Isabelle; Leunen Karin; Amant Frédéric; Van Gorp Toon; Neven Patrick; Vergote Ignace
The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Gynecologic oncology 2007;106(2):354-61.
2007: Cadron Isabelle; Leunen Karin; Van Gorp Toon; Amant Frederic; Neven Patrick; Vergote Ignace
Management of borderline ovarian neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(20):2928-37.
2007: Coosemans A; Nik S Amini; Caluwaerts S; Lambin S; Verbist G; Van Bree R; Schelfhout V; de Jonge E; Dalle I; Jacomen G; Cassiman J J; Moerman Ph; Vergote I; Amant F
Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas.
European journal of cancer (Oxford, England : 1990) 2007;43(10):1630-7.
2007: Morales Leilani; Pans Steven; Paridaens Robert; Westhovens Rene; Timmerman Dirk; Verhaeghe Johan; Wildiers Hans; Leunen Karin; Amant Frederic; Berteloot Patrick; Smeets Ann; Van Limbergen Erik; Weltens Caroline; Van den Bogaert Walter; De Smet Luc; Vergote Ignace; Christiaens Marie-Rose; Neven Patrick
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Breast cancer research and treatment 2007;104(1):87-91.
2007: Van den Bosch T; Van Schoubroeck D; Domali E; Vergote I; Moerman P; Amant F; Timmerman D
A thin and regular endometrium on ultrasound is very unlikely in patients with endometrial malignancy.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2007;29(6):674-9.
2007: Marth Christian; Egle Daniel; Auer Doris; Rössler Julia; Zeimet Alain G; Vergote Ignace; Daxenbichler Günter
Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab.
Gynecologic oncology 2007;105(3):716-21.
2007: Franchi M; Trimbos J B; Zanaboni F; v d Velden J; Reed N; Coens C; Teodorovic I; Vergote I
Randomised trial of drains versus no drains following radical hysterectomy and pelvic lymph node dissection: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) study in 234 patients.
European journal of cancer (Oxford, England : 1990) 2007;43(8):1265-8.
2007: Van Calster B; Timmerman D; Lu C; Suykens J A K; Valentin L; Van Holsbeke C; Amant F; Vergote I; Van Huffel S
Preoperative diagnosis of ovarian tumors using Bayesian kernel-based methods.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2007;29(5):496-504.
2007: Kalogiannidis Ioannis; Lambrechts Sandrijne; Amant Frederic; Neven Patrick; Van Gorp Toon; Vergote Ignace
Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome.
American journal of obstetrics and gynecology 2007;196(3):248.e1-8.
2007: Timmerman D; Van Holsbeke C; Van den Bosch T; Van Calster B; Van Huffel S; Vergote I
Re: "Comparison of diagnostic usefulness of predictive models in preliminary differentiation of adnexal masses".
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(2):543; author reply 544.
2007: Obermair Andreas; Fuller Arlan; Lopez-Varela Elisa; van Gorp Toon; Vergote Ignace; Eaton Lynne; Fowler Jeff; Quinn Michael; Hammond Ian; Marsden Donald; Proietto Anthony; Carter Jonathan; Davy Margaret; Tripcony Lee; Abu-Rustum Nadeem
A new prognostic model for FIGO stage 1 epithelial ovarian cancer.
Gynecologic oncology 2007;104(3):607-11.
2007: Vandenput I; Amant F; Neven P; Berteloot P; Leunen K; Vergote I
Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(1):83-7.
2007: Lambin Suzan; van Bree Rita; Caluwaerts Silvia; Vercruysse Lisbeth; Vergote Ignace; Verhaeghe Johan
Adipose tissue in offspring of Lepr(db/+) mice: early-life environment vs. genotype.
American journal of physiology. Endocrinology and metabolism 2007;292(1):E262-71.
2007: Van Gorp T; Amant F; Neven P; Berteloot P; Leunen K; Vergote I
The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer.
Cancer treatment and research 2007;134():387-402.
2006: Lambin Suzan; van Bree Rita; Vergote Ignace; Verhaeghe Johan
Chronic tumor necrosis factor-alpha infusion in gravid C57BL6/J mice accelerates adipose tissue development in female offspring.
Journal of the Society for Gynecologic Investigation 2006;13(8):558-65.
2006: Amant Frederic; Woestenborghs Heidi; Vandenbroucke Vanessa; Berteloot Patrick; Neven Patrick; Moerman Philippe; Vergote Ignace
Transition of endometrial stromal sarcoma into high-grade sarcoma.
Gynecologic oncology 2006;103(3):1137-40.
2006: Penson Richard T; Wenzel Lari B; Vergote Ignace; Cella David
Quality of life considerations in gynecologic cancer. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2006;95 Suppl 1():S247-57.
2006: Colombo Nicoletta; Van Gorp Toon; Parma Gabriella; Amant Frederic; Gatta Gemma; Sessa Cristiana; Vergote Ignace
Ovarian cancer.
Critical reviews in oncology/hematology 2006;60(2):159-79.
2006: Gore Martin; du Bois Andreas; Vergote Ignace
Intraperitoneal chemotherapy in ovarian cancer remains experimental.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4528-30.
2006: Van Gorp T; Amant F; Neven P; Berteloot P; Leunen K; Vergote I
The position of neoadjuvant chemotherapy within the treatment of ovarian cancer.
Minerva ginecologica 2006;58(5):393-403.
2006: Marquette Sophie; Amant Frederic; Vergote Ignace; Moerman Philippe
Pseudomyxoma peritonei associated with a mucinous ovarian tumor arising from a mature cystic teratoma. A case report.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2006;25(4):340-3.
2006: Pfisterer Jacobus; Plante Marie; Vergote Ignace; du Bois Andreas; Hirte Hal; Lacave Angel J; Wagner Uwe; Stähle Anne; Stuart Gavin; Kimmig Rainer; Olbricht Sigrid; Le Tien; Emerich Janusz; Kuhn Walther; Bentley James; Jackisch Christian; Lück Hans-Joachim; Rochon Justine; Zimmermann Annamaria Hayden; Eisenhauer Elizabeth;
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(29):4699-707.
2006: Green J A; Berns E M J J; Coens C; van Luijk I; Thompson-Hehir J; van Diest P; Verheijen R H M; van de Vijver M; van Dam P; Kenter G G; Tjalma W; Ewing P C; Teodorovic I; Vergote I; van der Burg M E L;
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865).
European journal of cancer (Oxford, England : 1990) 2006;42(15):2539-48.
2006: Van Gorp T; Vergote I B; Pochet N L M M; Amant F
Methodology in plasma proteomic pattern experiments.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(5):1951-2; author reply 1953.
2006: Kalogiannidis I; Lambrechts S; Amant F; Neven P; VAN Limbergen E; Vergote I
Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: An analysis of 208 patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(5):1885-93.
2006: Vergote Ignace; Amant Frederic
Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer.
Gynecologic oncology 2006;102(3):415-7.
2006: Vandenput Ingrid; Vergote Ignace; Amant Frederic; Neven Patrick; Paridaens Robert; Christiaens Marie-Rose
Aromatase inhibitors in premenopausal women: the need for proper contraceptive counseling.
The breast journal 2006;12(5):507-8.
2006: Cadron Isabelle; Amant Frederic; Van Gorp Toon; Neven Patrick; Leunen Karin; Vergote Ignace
The management of borderline tumours of the ovary.
Current opinion in oncology 2006;18(5):488-93.
2006: Gevaert Olivier; Pochet Nathalie; De Smet Frank; Van Gorp Toon; De Moor Bart; Timmerman Dirk; Amant Frédéric; Vergote Ignace
Molecular profiling of platinum resistant ovarian cancer: use of the model in clinical practice.
International journal of cancer. Journal international du cancer 2006;119(6):1511; author reply 1512.
2006: Neven Patrick; Pochet Nathalie; Drijkoningen Maria; Amant Frederic; De Smet Frank; Paridaens Robert; Christiaens Marie-Rose; Vergote Ignace
Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2595; author reply 2595-7.
2006: De Smet F; De Brabanter J; Van den Bosch T; Pochet N; Amant F; Van Holsbeke C; Moerman P; De Moor B; Vergote I; Timmerman D
New models to predict depth of infiltration in endometrial carcinoma based on transvaginal sonography.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2006;27(6):664-71.
2006: Marquette A; Moerman P; Vergote I; Amant F
Second case of uterine mesonephric adenocarcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(3):1450-4.
2006: Papanikolaou A; Kalogiannidis I; Goutzioulis M; Misailidou D; Makedos A; Vergote I; Makedos G
Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer.
Archives of gynecology and obstetrics 2006;274(2):91-6.
2006: Van Calsteren Kristel; Berteloot Patrick; Hanssens Myriam; Vergote Ignace; Amant Frederic; Ganame Javier; Claus Piet; Mertens Luc; Lagae Lieven; Delforge Michel; Paridaens Robert; Noens Lucien; Humblet Yves; Vandermeersch Bruno; De Muylder Xavier
In utero exposure to chemotherapy: effect on cardiac and neurologic outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):e16-7.
2006: Caluwaerts S; VAN Calsteren K; Mertens L; Lagae L; Moerman P; Hanssens M; Wuyts K; Vergote I; Amant F
Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(2):905-8.
2006: Despierre E; Moerman P; Vergote I; Amant F
Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 1():273-7.
2006: De Smet F; Pochet N L M M; Engelen K; Van Gorp T; Van Hummelen P; Marchal K; Amant F; Timmerman D; De Moor B L R; Vergote I B
Predicting the clinical behavior of ovarian cancer from gene expression profiles.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 1():147-51.
2006: Fuso L; Amant F; Neven P; Berteloot P; Vergote I
Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 1():60-7.
2006: Leunen K; Legius E; Moerman P; Amant F; Neven P; Vergote I
Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(1):183-8.
2006: Amant F; Leunen K; Neven P; Berteloot P; Vergote I
Endometrial cancer: predictors of response and preferred endocrine therapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 2():527-8.
2006: Vergote I; Amant F; Leunen K; Van Gorp T; Berteloot P; Neven P
Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 2():524-6.
2006: Neven P; Paridaens R; Amant F; Wildiers H; Berteloot P; Leunen K; Smeets A; Weltens C; van den Bogaert W; van Limbergen E; Christiaens M R; Vergote I
Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 2():505-10.
2006: Neven P; Vergote I; Amant F; Berteloot P; de Jonge E; DE Rop C; DE Sutter P; Makar A; VAN Ginderachter J
Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26-28, 2006.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 2():479-91.
2006: Amant F; Vandenput I; Van Gorp T; Vergote I; Moerman Ph
Endometrial carcinosarcoma with osteoclast-like giant cells.
European journal of gynaecological oncology 2006;27(1):92-4.
2005: Timmerman Dirk; Testa Antonia C; Bourne Tom; Ferrazzi Enrico; Ameye Lieveke; Konstantinovic Maja L; Van Calster Ben; Collins William P; Vergote Ignace; Van Huffel Sabine; Valentin Lil;
Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(34):8794-801.
2005: Vergote Ignace; van Gorp Toon; Amant Frederic; Neven Patrick; Berteloot Patrick
Neoadjuvant chemotherapy for ovarian cancer.
Oncology (Williston Park, N.Y.) 2005;19(12):1615-22; discussion 1623-30.
2005: van der Burg M E L; van der Gaast A; Vergote I; Burger C W; van Doorn H C; de Wit R; Stoter G; Verweij J
What is the role of dose-dense therapy?
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15 Suppl 3():233-40.
2005: Amant F; Moerman P; Vergote I
Report of an unusual problematic uterine smooth muscle neoplasm, emphasizing the prognostic importance of coagulative tumor cell necrosis.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(6):1210-2.
2005: De Smet Frank; Pochet Nathalie L M M; De Moor Bart L R; Van Gorp Toon; Timmerman Dirk; Vergote Ignace B; Hartmann Lynn C; Damokosh Andrew I; Hoersch Sebastian
Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7958-9; author reply 7959.
2005: Fruscella E; Testa A C; Ferrandina G; De Smet F; Van Holsbeke C; Scambia G; Zannoni G F; Ludovisi M; Achten R; Amant F; Vergote I; Timmerman D
Ultrasound features of different histopathological subtypes of borderline ovarian tumors.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2005;26(6):644-50.
2005: Huang H J; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens M R
Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(11):1755-61.
2005: Van Mieghem Tim; Abeler Vera M; Moerman Philippe; Verbist Lieve; Vergote Ignace; Amant Frederic
CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma.
Gynecologic oncology 2005;99(2):493-6.
2005: Caluwaerts S; Amant F; Vergote I
Role of cyclin-dependent kinase p27 in uterine carcinosarcomas.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(5):986-7; author reply 988.
2005: Van Calsteren K; Amant F; Vergote I
Role of adnexectomy in the surgical treatment of cervical adenocarcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(5):984; author reply 985.
2005: Vergote I; Marquette S; Amant F; Berteloot P; Neven P
Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(5):776-9.
2005: Vandenput I; Amant F; Vergote I
Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy.
Gynecologic oncology 2005;98(3):523; author reply 524-5.
2005: Amant Frederic; Moerman Philippe; Neven Patrick; Timmerman Dirk; Van Limbergen Erik; Vergote Ignace
Endometrial cancer.
Lancet 2005;366(9484):491-505.
2005: Amant Frederic; Cadron Isabelle; Fuso Luca; Berteloot Patrick; de Jonge Eric; Jacomen Gerd; Van Robaeys Johan; Neven Patrick; Moerman Philippe; Vergote Ignace
Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Gynecologic oncology 2005;98(2):274-80.
2005: Van Calsteren K; Vergote I; Amant F
Cervical neoplasia during pregnancy: diagnosis, management and prognosis.
Best practice & research. Clinical obstetrics & gynaecology 2005;19(4):611-30.
2005: Howell Anthony; Pippen John; Elledge Richard M; Mauriac Louis; Vergote Ignace; Jones Stephen E; Come Steven E; Osborne C Kent; Robertson John F R
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Cancer 2005;104(2):236-9.
2005: Huang H J; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens M R
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
Journal of clinical pathology 2005;58(6):611-6.
2005: Dodwell David; Vergote Ignace
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Cancer treatment reviews 2005;31(4):274-82.
2005: Huang Huei-Jean; Neven Patrick; Drijkoningen Maria; Paridaens Robert; Wildiers Hans; Van Limbergen Erik; Berteloot Patrick; Amant Frederic; Christiaens Marie Rose; Vergote Ignace
Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
Breast cancer research and treatment 2005;91(1):81-7.
2005: Morales L; Timmerman D; Neven P; Konstantinovic M L; Carbonez A; Van Huffel S; Ameye L; Weltens C; Christiaens M-R; Vergote I; Paridaens R
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):70-4.
2005: Thigpen T; Stuart G; du Bois A; Friedlander M; Fujiwara K; Guastalla J P; Kaye S; Kitchener H; Kristensen G; Mannel R; Meier W; Miller B; Poveda A; Provencher D; Stehman F; Vergote I;
Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 8():viii13-viii19.
2005: Cadron Isabelle; Jakobsen Anders; Vergote Ignace
Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.
Gynecologic and obstetric investigation 2005;59(3):126-9.
2004: Amant Frederic; Vloeberghs Veerle; Woestenborghs Heidi; Debiec-Rychter Maria; Verbist Lieve; Moerman Philippe; Vergote Ignace
ERBB-2 gene overexpression and amplification in uterine sarcomas.
Gynecologic oncology 2004;95(3):583-7.
2004: Amant F; Steenkiste E; Schurmans K; Verbist L; Abeler V M; Tulunay G; de Jonge E; Massuger L; Moerman P; Vergote I
Immunohistochemical expression of CD10 antigen in uterine adenosarcoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(6):1118-21.
2004: Morales Leilani; Neven Patrick; Timmerman Dirk; Christiaens Marie-Rose; Vergote Ignace; Van Limbergen Erik; Carbonez An; Van Huffel Sabine; Ameye Lieveke; Paridaens Robert
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Anti-cancer drugs 2004;15(8):753-60.
2004: Traen K; Logghe H; Maertens J; Mattelaere C; Moerman P; Vergote I
Endodermal sinus tumor of the vulva: successfully treated with high-dose chemotherapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(5):998-1003.
2004: De Smet F; Moreau Y; Engelen K; Timmerman D; Vergote I; De Moor B
Balancing false positives and false negatives for the detection of differential expression in malignancies.
British journal of cancer 2004;91(6):1160-5.
2004: Vergote Ignace B; Amant F
Early ovarian cancer--time for a rethink on stage?
Gynecologic oncology 2004;94(2):607; author reply 607-8.
2004: Amant Frederic; Schurmans Katrien; Steenkiste Edwin; Verbist Lieve; Abeler Vera M; Tulunay Gökhan; De Jonge Eric; Massuger Leon; Moerman Philippe; Vergote Ignace
Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma.
Gynecologic oncology 2004;93(3):680-5.
2004: Buzdar Aman U; Vergote Ignace; Sainsbury Richard
The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
The breast journal 2004;10(3):211-7.
2004: Van Gorp Toon; Amant Frederic; Neven Patrick; Vergote Ignace; Moerman Phillipe
Endometriosis and the development of malignant tumours of the pelvis. A review of literature.
Best practice & research. Clinical obstetrics & gynaecology 2004;18(2):349-71.
2004: Amant Frederic; Vergote Ignace
Importance of the endometrioid carcinoma subtype and sarcomatous component in uterine carcinosarcoma.
Gynecologic oncology 2004;93(1):272-3; author reply 273-4.
2004: Vergote Ignace
Adjuvant therapy for early staged (epithelial) cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(2):396; author reply 397.
2004: Rustin Gordon J S; Quinn Michael; Thigpen Tate; du Bois Andreas; Pujade-Lauraine Eric; Jakobsen Anders; Eisenhauer Elizabeth; Sagae Satoru; Greven Kathryn; Vergote Ignace; Cervantes Andres; Vermorken Jan
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
Journal of the National Cancer Institute 2004;96(6):487-8.
2004: Amant Frédéric; Dorfling Cecilia M; de Brabanter Jos; Vandewalle Joos; Vergote Ignace; Lindeque B G; van Rensburg Elizabeth J
A possible role of the cytochrome P450c17alpha gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study.
Acta obstetricia et gynecologica Scandinavica 2004;83(3):234-9.
2004: Trimbos J B; Franchi M; Zanaboni F; Velden J v d; Vergote I
'State of the art' of radical hysterectomy; current practice in European oncology centres.
European journal of cancer (Oxford, England : 1990) 2004;40(3):375-8.
2004: Wagenaar H C; Trimbos J B M Z; Teodorovic I; Therasse P; Vergote I
Medical fellowship programme within the Gynaecological Cancer Group of the European Organisation for Research and Treatment of Cancer.
Gynecologic and obstetric investigation 2004;57(2):66-71.
2003: Piccart M J; Floquet A; Scarfone G; Willemse P H B; Emerich J; Vergote I; Giurgea L; Coens C; Awada A; Vermorken J B
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():196-203.
2003: Kristensen G B; Vergote I; Stuart G; Del Campo J M; Kaern J; Lopez A B; Eisenhauer E; Aavall-Lundquist E; Ridderheim M; Havsteen H; Mirza M R; Scheistroen M; Vrdoljak E
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():172-7.
2003: Piccart M J; Bertelsen K; Stuart G; Cassidy J; Mangioni C; Simonsen E; James K; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson R; Swenerton K; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy J-A; Lhoas F; Lidvall B; Bacon M; Birt A; Andersen J; Zee B; Paul J; Pecorelli S; Baron B; McGuire W
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():144-8.
2003: Vergote Ignace; Trimbos Baptist J
Treatment of patients with early epithelial ovarian cancer.
Current opinion in oncology 2003;15(6):452-5.
2003: Amant Frederic; Lottering Mona Liza; Joubert Annie; Thaver Veneesha; Vergote Ignace; Lindeque B G
2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth.
Gynecologic oncology 2003;91(2):299-308.
2003: van der Burg Maria E L; Vergote Ignace;
The role of interval debulking surgery in ovarian cancer.
Current oncology reports 2003;5(6):473-81.
2003: Leunen Karin; Amant Frederic; Debiec-Rychter Maria; Croes Romaric; Hagemeijer Anne; Schoenmakers Eric F P M; Vergote Ignace
Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation.
Gynecologic oncology 2003;91(1):265-71.
2003: Kristensen G B; Kildal W; Abeler V M; Kaern J; Vergote I; Tropé C G; Danielsen H E
Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(10):1494-500.
2003: Amant Frederic; Vloeberghs Veerle; Woestenborghs Heidi; Moerman Philippe; Vergote Ignace
Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis.
Gynecologic oncology 2003;90(2):372-7.
2003: Lu C; Van Gestel T; Suykens J A K; Van Huffel S; Vergote I; Timmerman D
Preoperative prediction of malignancy of ovarian tumors using least squares support vector machines.
Artificial intelligence in medicine 2003;28(3):281-306.
2003: Gaarenstroom K N; Kenter G G; Trimbos J B; Agous I; Amant F; Peters A A W; Vergote I
Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(4):522-7.
2003: Timmerman Dirk; Neven Patrick; Deprest Jan; Konstantinovic Maja L; Vergote Ignace
Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women.
Cancer 2003;98(2):431-2; author reply 432-3.
2003: Robertson John F R; Osborne C Kent; Howell Anthony; Jones Stephen E; Mauriac Louis; Ellis Matthew; Kleeberg Ulrich R; Come Steven E; Vergote Ignace; Gertler Stan; Buzdar Aman; Webster Alan; Morris Charles
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Cancer 2003;98(2):229-38.
2003: Amant Frédéric; Moerman Philippe; Cadron Isabelle; Neven Patrick; Berteloot Patrick; Vergote Ignace
The diagnostic problem of endometrial stromal sarcoma: report on six cases.
Gynecologic oncology 2003;90(1):37-43.
2003: Benson Al; Poplin Elizabeth; Vergote Ignace
ZD9331 in combination with topotecan: phase I and II experience.
Anti-cancer drugs 2003;14 Suppl 1():S21-7.
2003: Hainsworth John; Vergote Ignace; Janssens Jacques
A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours.
Anti-cancer drugs 2003;14 Suppl 1():S13-9.
2003: Vergote I; Robertson J F R; Kleeberg U; Burton G; Osborne C K; Mauriac L;
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Breast cancer research and treatment 2003;79(2):207-11.
2003: Aapro M S; van Wijk F H; van der Burg M E L; ten Bokkel Huinink W; Vergote I; Guastalla J P; Rosso R; Kobierska A; Beex L V A; Namer M; Splinter T E W; Vermorken J B
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1141-3.
2003: van Rijswijk R E N; Vermorken J B; Reed N; Favalli G; Mendiola C; Zanaboni F; Mangili G; Vergote I; Guastalla J P; ten Bokkel Huinink W W; Lacave A J; Bonnefoi H; Tumulo S; Rietbroek R; Teodorovic I; Coens C; Pecorelli S
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).
European journal of cancer (Oxford, England : 1990) 2003;39(4):481-7.
2003: Amant Frédéric; Vergote Ignace
Bifunctional pathway of uterine carcinosarcomas.
Human pathology 2003;34(3):299; author reply 300.
2003: Amant Frédéric; Gabriel Charlotte; Moerman Philippe; Vergote Ignace
Immunohistochemical determination of hormone receptors in uterine adenosarcomas.
Gynecologic oncology 2003;88(3):463-4.
2003: Amant Frédéric; Moerman Philippe; Cadron Isabelle; Hagemeijer Anne; Vergote Ignace; Debiec-Rychter Maria
Endometrial stromal sarcoma with a sole t(X;17) chromosome change: report of a case and review of the literature.
Gynecologic oncology 2003;88(3):459-62.
2003: D'Agostino Giuseppe; Amant Frederic; Berteloot Patrick; Scambia Giovanni; Vergote Ignace
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
Gynecologic oncology 2003;88(3):266-9.
2003: Diamandis Eleftherios P; Scorilas Andreas; Fracchioli Stefano; Van Gramberen Marleen; De Bruijn Henk; Henrik Alfthan; Soosaipillai Antoninus; Grass Linda; Yousef George M; Stenman Ulf-Hakan; Massobrio Marco; Van Der Zee Ate G J; Vergote Ignace; Katsaros Dionyssios
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1035-43.
2003: Amant Frédéric; Huys Erik; Geurts-Moespot Anneke; Lindeque B G; Vergote Ignace; Sweep Fred; Schoenmakers Eric F P M
Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels.
Journal of the Society for Gynecologic Investigation 2003;10(2):105-9.
2003: Luo Liu-Ying; Katsaros Dionyssios; Scorilas Andreas; Fracchioli Stefano; Bellino Roberto; van Gramberen Marleen; de Bruijn Henk; Henrik Alfthan; Stenman Ulf-Hakan; Massobrio Marco; van der Zee Ate G J; Vergote Ignace; Diamandis Eleftherios P
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
Cancer research 2003;63(4):807-11.
2003: Keldsen Nina; Havsteen Hanne; Vergote Ignace; Bertelsen Kamma; Jakobsen Anders
Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.
Gynecologic oncology 2003;88(2):118-22.
2003: Trimbos J Baptist; Vergote Ignace; Bolis Giorgio; Vermorken Jan B; Mangioni Constantino; Madronal Caterina; Franchi Massimo; Tateo Saverio; Zanetta Gerardo; Scarfone Giovanna; Giurgea Livia; Timmers Petra; Coens Corneel; Pecorelli Sergio;
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Journal of the National Cancer Institute 2003;95(2):113-25.
2003: Trimbos J Baptist; Parmar Mahesh; Vergote Ignace; Guthrie David; Bolis Giorgio; Colombo Nicoletta; Vermorken Jan B; Torri Valter; Mangioni Constantino; Pecorelli Sergio; Lissoni Andrea; Swart Ann Marie;
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Journal of the National Cancer Institute 2003;95(2):105-12.
2003: Drieskens O; Stroobants S; Gysen M; Vandenbosch G; Mortelmans L; Vergote I
Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer.
Gynecologic and obstetric investigation 2003;55(3):130-4.
2002: Vergote I;
Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 6():S57-8.
2002: Neven P; Vergote I; Van Ginderachter J; van Dam P; Tjalma W; De Rop C; De Prins F
Endocrine treatment and prevention of breast and gynaecological cancers.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 6():S1-11.
2002: Howell A; Robertson J F R; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg U R; Vergote I; Erikstein B; Webster A; Morris C
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3396-403.
2002: Amant Frederic; Vergote Ignace
PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomas.
American journal of obstetrics and gynecology 2002;187(1):258.
2002: Amant F; de la Rey M; Dorfling C M; van der Walt L; Dreyer G; Dreyer L; Vergote I; Lindeque B G; Van Rensburg E J
PTEN mutations in uterine sarcomas.
Gynecologic oncology 2002;85(1):165-9.
2002: Vergote Ignace; De Smet Isabel; Amant Frédéric
Incidence of positive peritoneal cytology in low-risk endometrial cancer treated by laparoscopically assisted vaginal hysterectomy.
Gynecologic oncology 2002;84(3):537-8.
2002: Vergote Ignace; Amant F; Berteloot P; Van Gramberen M
Laparoscopic lower para-aortic staging lymphadenectomy in stage IB2, II, and III cervical cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2002;12(1):22-6.
2001: Amant F; Debiec-Rychter M; Schoenmakers E F; Hagemeijer-Hausman A; Vergote I
Cumulative dosage effect of a RAD51L1/HMGA2 fusion and RAD51L1 loss in a case of pseudo-Meigs' syndrome.
Genes, chromosomes & cancer 2001;32(4):324-9.
2001: Timmerman D; Verrelst H; Collins W P; Bourne T H; Vergote I
Re: Mol et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol 2001;80:162-7.
Gynecologic oncology 2001;83(1):166-8.
2001: Amant F; Gabriel C; Timmerman D; Vergote I
Pseudo-Meigs' syndrome caused by a hydropic degenerating uterine leiomyoma with elevated CA 125.
Gynecologic oncology 2001;83(1):153-7.
2001: Wagenaar H C; Colombo N; Vergote I; Hoctin-Boes G; Zanetta G; Pecorelli S; Lacave A J; van Hoesel Q; Cervantes A; Bolis G; Namer M; Lhommé C; Guastalla J P; Nooij M A; Poveda A; Scotto di Palumbo V; Vermorken J B
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
Gynecologic oncology 2001;81(3):348-54.
2001: Amant F; Dorfling C M; Dreyer L; Vergote I; Lindeque B G; Van Rensburg E J
Microsatellite instability in uterine sarcomas.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2001;11(3):218-23.
2001: Amant F; Moerman P; Davel G H; De Vos R; Vergote I; Lindeque B G; de Jonge E
Uterine carcinosarcoma with melanocytic differentiation.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2001;20(2):186-90.
2001: Duffaud F; van der Burg M E; Namer M; Vergote I; Willemse PHB; ten Bokkel Huinink W; Guastalla J P; Nooij; Kerbrat P; Piccart M; Tumolo S; Favalli G; van der Vange N; Lacave A J; Wils J; Splinter T A; Einhorn N; Roozendaal K J; Rosso R; Vermorken J B
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.
Anti-cancer drugs 2001;12(2):159-62.
2001: Vergote I; De Brabanter J; Fyles A; Bertelsen K; Einhorn N; Sevelda P; Gore M E; Kaern J; Verrelst H; Sjövall K; Timmerman D; Vandewalle J; Van Gramberen M; Tropé C G
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.
Lancet 2001;357(9251):176-82.
2001: Amant F; Dreyer L; Makin J; Vergote I; Lindeque B G
Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations.
European journal of gynaecological oncology 2001;22(3):194-200.
2001: Wagenaar H C; Pecorelli S; Vergote I; Curran D; Wagener D J; Kobierska A; Bolis G; Bokkel-Huinink W T; Lacave A J; Madronal C; Forn M; de Oliveira C F; Mangioni C; Nooij M A; Goupil A; Kerbrat P; Marth C H; Tumolo S; Herben M G; Zanaboni F; Vermorken J B
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.
European journal of gynaecological oncology 2001;22(3):187-93.
2000: Hoskins P; Eisenhauer E; Vergote I; Dubuc-Lissoir J; Fisher B; Grimshaw R; Oza A; Plante M; Stuart G; Vermorken J
Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4038-44.
2000: Bonneterre J; Thürlimann B; Robertson J F; Krzakowski M; Mauriac L; Koralewski P; Vergote I; Webster A; Steinberg M; von Euler M
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(22):3748-57.
2000: Timmerman D; Valentin L; Bourne T H; Collins W P; Verrelst H; Vergote I;
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2000;16(5):500-5.
2000: Vergote I; Bonneterre J; Thürlimann B; Robertson J; Krzakowski M; Mauriac L; Koralewski L; Webster A; Steinberg M; von Euler M
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
European journal of cancer (Oxford, England : 1990) 2000;36 Suppl 4():S84-5.
2000: Timmerman D; Deprest J; Verbesselt R; Moerman P; De Brabanter J; Vergote I
Absence of correlation between risk factors for endometrial cancer and the presence of tamoxifen-associated endometrial polyps in postmenopausal patients with breast cancer.
European journal of cancer (Oxford, England : 1990) 2000;36 Suppl 4():S40-2.
2000: Vergote I; Neven P; van Dam P; Serreyn R; De Prins F; De Sutter P; Albertyn G
The oestrogen receptor and its selective modulators in gynaecological and breast cancer.
European journal of cancer (Oxford, England : 1990) 2000;36 Suppl 4():S1-9.
2000: Vergote I B; De Wever I; Decloedt J; Tjalma W; Van Gramberen M; van Dam P
Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Seminars in oncology 2000;27(3 Suppl 7):31-6.
2000: Piccart M J; Bertelsen K; James K; Cassidy J; Mangioni C; Simonsen E; Stuart G; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson R J; Swenerton K D; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy J A; Lhoas F; Lindvall B; Bacon M; Birt A; Andersen J E; Zee B; Paul J; Baron B; Pecorelli S
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Journal of the National Cancer Institute 2000;92(9):699-708.
2000: Tropé C; Kaern J; Hogberg T; Abeler V; Hagen B; Kristensen G; Onsrud M; Pettersen E; Rosenberg P; Sandvei R; Sundfor K; Vergote I
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(3):281-8.
2000: Piccart M J; Green J A; Lacave A J; Reed N; Vergote I; Benedetti-Panici P; Bonetti A; Kristeller-Tome V; Fernandez C M; Curran D; Van Glabbeke M; Lacombe D; Pinel M C; Pecorelli S
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1193-202.
2000: Scheidt P; Moerman P H; Vergote I
Rhabdomyosarcoma of the corpus of the uterus: a case report.
European journal of gynaecological oncology 2000;21(4):371-3.
2000: Tropé C G; Kisic J; Vergote I
Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide.
European journal of gynaecological oncology 2000;21(3):255-9.
1999: Pecorelli S; Wagenaar H C; Vergote I B; Curran D; Beex L V; Wiltshaw E; Vermorken J B
Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group study.
European journal of cancer (Oxford, England : 1990) 1999;35(9):1331-7.
1999: van Dam P A; DeCloedt J; Tjalma W A; Buytaert P; Becquart D; Vergote I B
Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced?
American journal of obstetrics and gynecology 1999;181(3):536-41.
1999: Timmerman D; Bourne T H; Tailor A; Collins W P; Verrelst H; Vandenberghe K; Vergote I
A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model.
American journal of obstetrics and gynecology 1999;181(1):57-65.
1999: Decloedt J; Vergote I
Laparoscopy in gynaecologic oncology: a review.
Critical reviews in oncology/hematology 1999;31(1):15-26.
1999: Timmerman D; Verrelst H; Bourne T H; De Moor B; Collins W P; Vergote I; Vandewalle J
Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 1999;13(1):17-25.
1999: Timmerman D; Schwärzler P; Collins W P; Claerhout F; Coenen M; Amant F; Vergote I; Bourne T H
Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 1999;13(1):11-6.
1999: Vandeginste S; Vergote I B; Hanssens M; Moerman P; Page G; Van Den Berghe K; Van Assche A
Malignant trophoblastic disease following a twin pregnancy consisting of a complete hydatiform mole and a normal fetus and placenta. A case report.
European journal of gynaecological oncology 1999;20(2):105-7.
1998: Vergote I; De Wever I; Tjalma W; Van Gramberen M; Decloedt J; van Dam P
Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.
Gynecologic oncology 1998;71(3):431-6.
1998: Amant F; Berteloot P; Vergote I
Gastrostomy using a "Gastrofix" as an alternative for nasogastric tubes in ovarian cancer surgery.
Gynecologic oncology 1998;71(3):348-51.
1998: Vergote I; Neven P; Vanderick G; van Dam P; Van Belle Y; De Sutter P h; De Prins F; De Muylder X; Claerhout J; Campo R; Albertyn G
Tamoxifen and the uterus.
European journal of cancer (Oxford, England : 1990) 1998;34 Suppl 4():S1-3.
1998: Timmerman D; Deprest J; Bourne T; Van den Berghe I; Collins W P; Vergote I
A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen.
American journal of obstetrics and gynecology 1998;179(1):62-70.
1998: Dal Cin P; Timmerman D; Van den Berghe I; Wanschura S; Kazmierczak B; Vergote I; Deprest J; Neven P; Moerman P; Bullerdiek J; Van den Berghe H
Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen.
Cancer research 1998;58(11):2278-81.
1998: Hellemans H; Moerman P; Timmerman D; Vergote I
Anaplastic nodules in an ovarian mucinous tumor. Case report and literature review.
European journal of gynaecological oncology 1998;19(6):529-33.
1997: Decloedt J; Berteloot P; Vergote I
The feasibility of open laparoscopy in gynecologic-oncologic patients.
Gynecologic oncology 1997;66(1):138-40.
1996: Timmerman D; Vergote I
Images in clinical medicine. Tamoxifen-induced endometrial polyp.
The New England journal of medicine 1996;335(22):1650.
1996: Assikis V J; Neven P; Jordan V C; Vergote I
A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1464-76.
1996: Vergote I B; Witters I; Moerman P; Timmerman D; Spitz B; Van Assche F A
Case report: mixed germ cell tumour of the ovary presenting as a missed abortion.
European journal of gynaecological oncology 1996;17(6):518-9.
1995: Timmerman D; Moerman P; Vergote I
Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature.
Gynecologic oncology 1995;59(3):405-8.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Ignace Vergote

Research Profile (preview)

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Ignace Vergote (preview)

All Publications